Intermittent plasminogen-streptokinase treatment of deep vein thrombosis.
The fibrinolytic response of 12 patients receiving single daily infusions of 600,000 units of streptokinase (SK) and 90 mg of plasminogen for the treatment of DVT has been studied. The mean plasminogen concentration was maintained throughout the treatment period (4-6 days) at between 20-40% the initial value, while mean circulating plasmin concentration rose to only about twice initial plasma levels. The degradation of fibrinogen as indicated by a fall in clottable fibrinogen did not fall below 1 mg/ml and serum FDP rose to greater than 1 mg/ml. Limited fibrinogenolysis occurred in 2 patients, while in another patient who bled there was immediate and extensive depletion to below 0.5 mg/ml. The beneficial clinical results obtained with this regimen (Kakkar et al. 1975), which produces only limited systemic plasminaemia, suggest that thrombolysis may be facilitated by higher levels of plasminogen than those maintained during conventional SK treatment.
D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D006801:Humans; D010958:Plasminogen / Q000008:administration & dosage* / Q000627:therapeutic use; D013300:Streptokinase / Q000008:administration & dosage* / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy*
D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen; D010958:Plasminogen; D013300:Streptokinase; D005341:Fibrinolysin